Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
Status:
Terminated
Trial end date:
2018-01-26
Target enrollment:
Participant gender:
Summary
A Phase 3b, open-label, randomized, multicenter, efficacy, safety, and tolerability study of
ITCA 650 compared to Empagliflozin and to Glimepiride, as add-on therapy to Metformin in
patients with Type 2 diabetes.